Building on the positive clinical and safety data from its lead drug nomacopan, Akari is developing a second related therapeutic candidate (votucalis) focusing …
PRESS RELEASES
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
NEW YORK and LONDON, January 6, 2021 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Participate in Two January Virtual Investor Conferences
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and …
